中国药业2016，Vol.25Issue(3)：21-23,24,4.
乳腺癌患者基质金属蛋白酶抑制因子－1和人类表皮生长因子受体－2表达的临床意义研究
Clinical Significance of TIMP-1 and HER-2 Expression in Breast Cancer Patients
庞菁春 1樊静1
作者信息
- 1. 重庆医科大学附属第一医院，重庆 400021
- 折叠
摘要
Abstract
Objective To investigate the clinical significance of tissue inhibitors of metalloproteinase-1 ( TIMP-1 ) and human epider-mal growth factor receptor 2 ( HER-2 ) expression in breast cancer patients. Methods 98 breast cancer patients from January 2006 to December 2007 were collected and followed-up for 5 years, then the relations between TIMP-1, HER-2 and clinical pathological features of breast cancer patients were analyzed, and the overall survival ( OS ) was applied to assess the patients' prognosis. Results The rate of TIMP-1 positive expression was 57. 14%, and HER-2 was 42. 86%. The TMP-1 and HER-2 expressions and patient age, tumor size, clinical stage and histological type were irrelevant ( P ﹥ 0. 05 );TIMP-1 expression and lymph node metastasis, histologi-cal grade were relevant ( P ﹤ 0. 05 );HER-2 and ER, PR status information were relevant ( P ﹤ 0. 05 ) , the 5-year survival rate of pa-tients with TIMP-1 expression ( 61. 79%) was less than that of patients with no TIMP-1 expression ( 66. 64%) , and there was no sta-tistical difference ( P ﹥ 0. 05 );the 5-year survival rate of patients HER-2 expression ( 56. 43%) was significantly lower than that of pa-tients with the negative HER-2 expression ( 64. 32%) , and there was statistical difference ( P ﹤ 0. 05 ) . Conclusion TIMP-1 expression is related to lymphatic metastasis and tissue differentiation but it may be not an independent predictor of poor prognosis. The 5-year survival rate of HER-2 positive expression is significantly lower, which could be used as an adverse prognostic indicator.关键词
金属蛋白酶抑制剂/基质金属蛋白酶抑制因子-1/人类表皮生长因子受体-2/乳腺恶性肿瘤Key words
metalloproteinase inhibitor/TIMP-1/HER-2/malignant breast tumors分类
医药卫生引用本文复制引用
庞菁春,樊静..乳腺癌患者基质金属蛋白酶抑制因子－1和人类表皮生长因子受体－2表达的临床意义研究[J].中国药业,2016,25(3):21-23,24,4.
